TD Cowen Maintains Hold on Myriad Genetics, Lowers Price Target to $6
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the price target from $7 to $6.
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the price target from $7 to $6.